摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(2'-deoxy-β-D-erythro-pentofuranosyl)-4-(methylsulfonyl)-1H-imidazo<4,5-c>pyridine | 144427-92-9

中文名称
——
中文别名
——
英文名称
1-(2'-deoxy-β-D-erythro-pentofuranosyl)-4-(methylsulfonyl)-1H-imidazo<4,5-c>pyridine
英文别名
1-(2'-deoxy-β-D-erythro-pentofuranosyl)-4-(methylsulfonyl)-1H-imidazo[4,5-c]pyridine;(2R,3S,5R)-2-(hydroxymethyl)-5-(4-methylsulfonylimidazo[4,5-c]pyridin-1-yl)oxolan-3-ol
1-(2'-deoxy-β-D-erythro-pentofuranosyl)-4-(methylsulfonyl)-1H-imidazo<4,5-c>pyridine化学式
CAS
144427-92-9
化学式
C12H15N3O5S
mdl
——
分子量
313.334
InChiKey
PGBXRIZSQPMUOE-IVZWLZJFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    703.4±70.0 °C(Predicted)
  • 密度:
    1.73±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.7
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    123
  • 氢给体数:
    2
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-(2'-deoxy-β-D-erythro-pentofuranosyl)-4-(methylsulfonyl)-1H-imidazo<4,5-c>pyridineammonium hydroxide双氧水 作用下, 反应 24.0h, 以47%的产率得到1-(2-脱氧-beta-D-赤式-呋喃戊糖基)-1H-咪唑并[4,5-c]吡啶-4-胺
    参考文献:
    名称:
    3-Deaza-2'-脱氧腺苷:通过4-(甲硫基)-1 H-咪唑并[4,5 - c ]吡啶2'-脱氧核糖核苷的合成及寡核苷酸的性质
    摘要:
    合成4-(甲硫基)-1 H ^ -咪唑并[4,5- c ^ ]吡啶2'-脱氧β-d核糖核苷2和9和的转换Ñ 1异构体2到2',3描述了'-didehydro-2',3'-dideoxy核糖核苷3a或(经由7)3-deaza-2'-脱氧腺苷(1)。的膦酸酯积木1自互补碱基修饰的寡核苷酸的固相合成中使用。就双链体稳定性和通过限制性酶Eco RI的水解而言,研究了它们的性质。
    DOI:
    10.1002/hlca.19920750519
  • 作为产物:
    参考文献:
    名称:
    3-Deaza-2'-脱氧腺苷:通过4-(甲硫基)-1 H-咪唑并[4,5 - c ]吡啶2'-脱氧核糖核苷的合成及寡核苷酸的性质
    摘要:
    合成4-(甲硫基)-1 H ^ -咪唑并[4,5- c ^ ]吡啶2'-脱氧β-d核糖核苷2和9和的转换Ñ 1异构体2到2',3描述了'-didehydro-2',3'-dideoxy核糖核苷3a或(经由7)3-deaza-2'-脱氧腺苷(1)。的膦酸酯积木1自互补碱基修饰的寡核苷酸的固相合成中使用。就双链体稳定性和通过限制性酶Eco RI的水解而言,研究了它们的性质。
    DOI:
    10.1002/hlca.19920750519
点击查看最新优质反应信息

文献信息

  • 3-Deaza-2?-deoxyadenosine: Synthesisvia 4-(methylthio)-1H-imidazo[4,5-c]pyridine 2?-deoxyribonucleosides and properties of oligonucleotides
    作者:Frank Seela、Thomas Grein、Samuel Samnick
    DOI:10.1002/hlca.19920750519
    日期:1992.8.13
    The synthesis of 4-(methylthio)-1H-imidazo[4,5-c]pyridine 2′-deoxy-β-D-ribonucleosides 2 and 9 and the conversion of the N1-isomer 2 into the 2′,3′-didehydro-2′,3′-dideoxyribonucleoside 3a or (via7) 3-deaza-2′-deoxyadenosine (1) is described. Phosphonate building blocks of 1 were employed in solid-phase synthesis of self-complementary base-modified oligonucleotides. Their properties were studied with
    合成4-(甲硫基)-1 H ^ -咪唑并[4,5- c ^ ]吡啶2'-脱氧β-d核糖核苷2和9和的转换Ñ 1异构体2到2',3描述了'-didehydro-2',3'-dideoxy核糖核苷3a或(经由7)3-deaza-2'-脱氧腺苷(1)。的膦酸酯积木1自互补碱基修饰的寡核苷酸的固相合成中使用。就双链体稳定性和通过限制性酶Eco RI的水解而言,研究了它们的性质。
查看更多

同类化合物

4-氨基-1-(2’,3’,5’-三-O-叔-丁基二甲基硅烷基-beta-D-呋喃核糖基)-咪唑并[4,5-a]吡啶 3-脱氮腺苷 3-去氮杂鸟苷酸 3-去氮杂鸟苷三磷酸酯 3-去氮杂鸟苷 1-(2-脱氧-beta-D-赤式-呋喃戊糖基)-1H-咪唑并[4,5-c]吡啶-4-胺 1-(2,3,5-三-O-乙酰基-beta-D-呋喃核糖基)-4,6-二氯咪唑并[4,5-c]吡啶 5'-O-(N-L-seryl)sulfamoyl-3-deaza-adenosine 5'-O-(N-glycyl)sulfamoyl-3-deaza-adenosine 5'-O-(N-L-isoleucyl)sulfamoyl-3-deaza-adenosine 2-Fluoro-3-deaza-adenosine 4-(pyridin-3-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-(pyrrol-3-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-(pyrrol-2-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-(furan-2-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 1-(β-D-ribofuranosyl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine 4-cyclopropyl-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-methyl-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 1-(β-D-ribofuranosyl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine Adenosine, 3-deaza- (2R,3S,5R)-5-(4-Dimethylamino-imidazo[4,5-c]pyridin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol (2R,3S,5R)-2-Hydroxymethyl-5-(4-mercapto-imidazo[4,5-c]pyridin-1-yl)-tetrahydro-furan-3-ol 4-chloro-7-fluoro-1-(2'-C-methyl-β-D-ribofuranosyl)-imidazo[4,5-c]pyridine 4-ethyl-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine (2R,3S,5R)-5-(4-Benzylamino-imidazo[4,5-c]pyridin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol 4-(Methylsulfanyl)-1-pentofuranosyl-1H-imidazo[4,5-c]pyridine 4,7-difluoro-1-(2,3,5-tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-imidazo[4,5-c]pyridine 6-Chloro-n,n-dimethyl-1-pentofuranosyl-1h-imidazo[4,5-c]pyridin-4-amine 2-(6-Chloro-4-methoxyimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 2-(4-Benzylsulfanyl-6-chloroimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 2-(6-Chloro-4-methylsulfanylimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol N-[4-bromo-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazo[4,5-c]pyridin-6-yl]acetamide 5,6-Diamino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazo[4,5-c]pyridin-4-one 1-amino-3-deazaguanosine 3-deazainosine 6-chloro-4-(cyclohexylamino)-1-(3-deoxy-β-D-ribofuranosyl)-1H-imidazo<4,5-c>pyridine [(2R,3R,4R,5R)-3,4-dibenzoyloxy-5-(4,6-dichloroimidazo[4,5-c]pyridin-1-yl)-4-methyloxolan-2-yl]methyl benzoate 4-amino-6-chloro-1-(3-deoxy-β-D-ribofuranosyl)-1H-imidazo<4,5-c>pyridine 4-amino-1-(2-deoxy-b-d-ribofuranosyl)-7-(1-naphthylethynyl)-imidazo[4,5-c]pyridine 3-Deazaguanosine 3',5'-cyclic phosphate 4-chloro-7-fluoro-1-(β-D-ribofuranosyl)imidazo[4,5-c]pyridine (2R,3S,5R)-5-(4-Benzylsulfanyl-imidazo[4,5-c]pyridin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol 4-(1H-pyrazol-5-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 2-bromo-5-methyl-1-(2,3,5-tri-O-t-butyldimethyl-silyl-β-D-ribofuranosyl)imidazo[4,5-c]pyridin-4(5H)-one 4-amino-6-fluoro-1-(2,3,5-tri-O-benzyl-β-D-arabinofuranosyl)imidazo[4,5-c]pyridine 4-amino-6-fluoro-1-(2,3,5-tri-O-benzyl-α-D-arabinofuranosyl)imidazo[4,5-c]pyridine 4-chloro-1-(2',3'-dideoxy-α-D-glycero-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 4-chloro-1-(2',3'-dideoxy-5'-O-<(1'',1 ''-dimethylethyl)dimethylsilyl>-β-D-glycero-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 4-chloro-1-(2',3'-dideoxy-5'-O-<(1'',1 ''-dimethylethyl)dimethylsilyl>-α-D-glycero-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 4-(furan-3-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine